# **Study population counts**

## Counts by exposure cohort

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acute myocardial infarction | Users of abiraterone + prednisone with CRPC (n = 6,645) | MDCR | 2,474 | 37.23 |
| Optum | 4,171 | 62.77 |
| Users of enzalutamide with CRPC (n = 7,005) | MDCR | 3,052 | 43.57 |
| Optum | 3,953 | 56.43 |
| Alzheimers/dementia/cognative decline | Users of abiraterone + prednisone with CRPC (n = 6,645) | MDCR | 2,474 | 37.23 |
| Optum | 4,171 | 62.77 |
| Users of enzalutamide with CRPC (n = 7,005) | MDCR | 3,052 | 43.57 |
| Optum | 3,953 | 56.43 |
| Cardiovascular morbidity (composite) | Users of abiraterone + prednisone with CRPC (n = 6,645) | MDCR | 2,474 | 37.23 |
| Optum | 4,171 | 62.77 |
| Users of enzalutamide with CRPC (n = 7,005) | MDCR | 3,052 | 43.57 |
| Optum | 3,953 | 56.43 |
| Heart failure | Users of abiraterone + prednisone with CRPC (n = 6,645) | MDCR | 2,474 | 37.23 |
| Optum | 4,171 | 62.77 |
| Users of enzalutamide with CRPC (n = 7,005) | MDCR | 3,052 | 43.57 |
| Optum | 3,953 | 56.43 |
| Hemorrhagic stroke | Users of abiraterone + prednisone with CRPC (n = 6,645) | MDCR | 2,474 | 37.23 |
| Optum | 4,171 | 62.77 |
| Users of enzalutamide with CRPC (n = 7,005) | MDCR | 3,052 | 43.57 |
| Optum | 3,953 | 56.43 |
| Ischemic stroke | Users of abiraterone + prednisone with CRPC (n = 6,645) | MDCR | 2,474 | 37.23 |
| Optum | 4,171 | 62.77 |
| Users of enzalutamide with CRPC (n = 7,005) | MDCR | 3,052 | 43.57 |
| Optum | 3,953 | 56.43 |
| Sudden cardiac death | Users of abiraterone + prednisone with CRPC (n = 6,645) | MDCR | 2,474 | 37.23 |
| Optum | 4,171 | 62.77 |
| Users of enzalutamide with CRPC (n = 7,005) | MDCR | 3,052 | 43.57 |
| Optum | 3,953 | 56.43 |

## Counts by database

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Acute myocardial infarction | MDCR (n = 5,526) | Users of abiraterone + prednisone with CRPC | 2,474 | 44.77 |
| Users of enzalutamide with CRPC | 3,052 | 55.23 |
| Optum (n = 8,124) | Users of abiraterone + prednisone with CRPC | 4,171 | 51.34 |
| Users of enzalutamide with CRPC | 3,953 | 48.66 |
| Alzheimers/dementia/cognative decline | MDCR (n = 5,526) | Users of abiraterone + prednisone with CRPC | 2,474 | 44.77 |
| Users of enzalutamide with CRPC | 3,052 | 55.23 |
| Optum (n = 8,124) | Users of abiraterone + prednisone with CRPC | 4,171 | 51.34 |
| Users of enzalutamide with CRPC | 3,953 | 48.66 |
| Cardiovascular morbidity (composite) | MDCR (n = 5,526) | Users of abiraterone + prednisone with CRPC | 2,474 | 44.77 |
| Users of enzalutamide with CRPC | 3,052 | 55.23 |
| Optum (n = 8,124) | Users of abiraterone + prednisone with CRPC | 4,171 | 51.34 |
| Users of enzalutamide with CRPC | 3,953 | 48.66 |
| Heart failure | MDCR (n = 5,526) | Users of abiraterone + prednisone with CRPC | 2,474 | 44.77 |
| Users of enzalutamide with CRPC | 3,052 | 55.23 |
| Optum (n = 8,124) | Users of abiraterone + prednisone with CRPC | 4,171 | 51.34 |
| Users of enzalutamide with CRPC | 3,953 | 48.66 |
| Hemorrhagic stroke | MDCR (n = 5,526) | Users of abiraterone + prednisone with CRPC | 2,474 | 44.77 |
| Users of enzalutamide with CRPC | 3,052 | 55.23 |
| Optum (n = 8,124) | Users of abiraterone + prednisone with CRPC | 4,171 | 51.34 |
| Users of enzalutamide with CRPC | 3,953 | 48.66 |
| Ischemic stroke | MDCR (n = 5,526) | Users of abiraterone + prednisone with CRPC | 2,474 | 44.77 |
| Users of enzalutamide with CRPC | 3,052 | 55.23 |
| Optum (n = 8,124) | Users of abiraterone + prednisone with CRPC | 4,171 | 51.34 |
| Users of enzalutamide with CRPC | 3,953 | 48.66 |
| Sudden cardiac death | MDCR (n = 5,526) | Users of abiraterone + prednisone with CRPC | 2,474 | 44.77 |
| Users of enzalutamide with CRPC | 3,052 | 55.23 |
| Optum (n = 8,124) | Users of abiraterone + prednisone with CRPC | 4,171 | 51.34 |
| Users of enzalutamide with CRPC | 3,953 | 48.66 |